US Pharma MarketingNovartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies about the next steps for its dystrophy prospect.
Source: FierceBiotech